Experienced in Mesenchymoma

Dr. Ami N. Shah

Hematology | Oncology
Northwestern Medical Group
4405 Weaver Pkwy, 
Waterman, IL 
Offers Telehealth
15 Years of Experience
Experienced in Mesenchymoma
Northwestern Medical Group
4405 Weaver Pkwy, 
Waterman, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ami Shah is a Hematologist and an Oncologist in Waterman, Illinois. Dr. Shah has been practicing medicine for over 15 years and is rated as an Experienced provider by MediFind in the treatment of Mesenchymoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Gastrostomy, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 143 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Northwestern University Feinberg School Of Medicine, 2011.0
Residency
McGaw Medical Center of Northwestern University
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Hematology (Certified)
Fellowships
McGaw Medical Center of Northwestern University
Hospital Affiliations
Northwestern Memorial Hospital
Palos Community Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 15 Less Insurance Carriers -

Locations

4405 Weaver Pkwy, Waterman, IL 60555
Call: 815-344-2300

Additional Areas of Focus

Dr. Shah has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
Enrollment Status: Active_not_recruiting
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: Gedatolisib, Talazoparib
Study Phase: Phase 1/Phase 2
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
View 6 Less Clinical Trials

143 Total Publications

Divergence Between Net Fluid and Weight-Based Evaluation in Calculating Cumulative Fluid Balance.
Divergence Between Net Fluid and Weight-Based Evaluation in Calculating Cumulative Fluid Balance.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
View All 143 Publications
Similar Doctors
Distinguished in Mesenchymoma
Dr. Samir D. Undevia
Hematology | Oncology
Distinguished in Mesenchymoma
Dr. Samir D. Undevia
Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, Fl 3, 
Naperville, IL 
 (4.4 miles away)
630-527-5359
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Samir Undevia is a Hematologist and an Oncologist in Naperville, Illinois. Dr. Undevia is rated as a Distinguished provider by MediFind in the treatment of Mesenchymoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Epithelioid Sarcoma. Dr. Undevia is currently accepting new patients.

Distinguished in Mesenchymoma
Dr. Bruce E. Brockstein
Oncology
Distinguished in Mesenchymoma
Dr. Bruce E. Brockstein
Oncology

Endeavor Health Medical Group

2650 Ridge Ave, 
Evanston, IL 
 (30.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Brockstein is an Oncologist in Evanston, Illinois. Dr. Brockstein is rated as a Distinguished provider by MediFind in the treatment of Mesenchymoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Undifferentiated Pleomorphic Sarcoma, Adult Soft Tissue Sarcoma, and Mesenchymoma. Dr. Brockstein is currently accepting new patients.

Pedro A. Hermida
Distinguished in Mesenchymoma
Dr. Pedro A. Hermida
Hematology | Oncology
Distinguished in Mesenchymoma
Dr. Pedro A. Hermida
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (29.6 miles away)
866-587-4322
Experience:
7+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pedro Hermida is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Hermida has been practicing medicine for over 7 years and is rated as a Distinguished provider by MediFind in the treatment of Mesenchymoma. His top areas of expertise are Bone Tumor, Synovial Sarcoma, Rhabdoid Tumor, Rhabdoid Tumor Predisposition Syndrome, and Gamma Knife Radiosurgery.

VIEW MORE MESENCHYMOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
  • Elite
  • Breast Cancer
    Dr. Shah is
    Elite
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Distinguished
  • Angiosarcoma
    Dr. Shah is
    Distinguished
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Paget Disease of the Breast
    Dr. Shah is
    Distinguished
    . Learn about Paget Disease of the Breast.
    See more Paget Disease of the Breast experts
  • Advanced
  • Gastrostomy
    Dr. Shah is
    Advanced
    . Learn about Gastrostomy.
    See more Gastrostomy experts
  • Inflammatory Breast Cancer
    Dr. Shah is
    Advanced
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
  • Systemic Sclerosis (SSc)
    Dr. Shah is
    Advanced
    . Learn about Systemic Sclerosis (SSc).
    See more Systemic Sclerosis (SSc) experts
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Shah is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Adult Soft Tissue Sarcoma
    Dr. Shah is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Anemia
    Dr. Shah is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Bone Marrow Aspiration
    Dr. Shah is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Bone Marrow Transplant
    Dr. Shah is
    Experienced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Congenital Hemolytic Anemia
    Dr. Shah is
    Experienced
    . Learn about Congenital Hemolytic Anemia.
    See more Congenital Hemolytic Anemia experts
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.